<p><strong>今天，eXoZymes Inc.（NASDAQ:EXOZ）（&#34;eXoZymes&#34;）</strong>- 一家利用人工智能增强酶将可持续原料转化为营养保健品和新药物的先锋公司 - 宣布成功实现其 N-trans-caffeoyltyramine（NCT）生产过程的 100 倍规模化，使用其专有的基于外源酶的无细胞生物制造平台。该努力在原料到产品的转化水平超过 99%，标志着外源酶平台可扩展性的一个重要里程碑。</p>
<p>&#34; <em>在保持高原料转化的同时将复杂的生物催化反应规模化 100 倍，增强了我们对外源酶将成为下一代生物制造基础的信心</em>，&#34; eXoZymes 首席执行官 Michael Heltzen 表示。&#34; <em>我们对这一进展感到非常兴奋，并将其视为一个重要的转折点，证明无细胞、酶驱动的系统可以被设计为在规模上可靠运行。这真正为生产历史上受传统制造方法限制的分子打开了大门</em>。&#34;</p>
<p>该规模化反应保持了极高的转化效率，在大容量操作条件下几乎完全将输入原料转化为目标产品。这一表现确认了外源酶驱动的过程不仅线性扩展，而且可以匹配或超过在小规模下观察到的转化水平。批量生产是在合作伙伴 Cayman Chemical 的操作条件下，使用标准化协议执行的，突显了该过程和技术的稳健性、可转移性和可扩展性。</p>
<p>eXoZymes 首席科学官 Dr. Tyler Korman 补充道，&#34; <em>在保持反应性能的同时进行规模化历来是一个挑战，而这一结果支持了越来越多的证据，表明无细胞酶生产路径 - 即外源酶系统 - 可以克服与传统生物制造方法相关的基本限制。在规模上实现超过 99% 的转化是我们外源酶生物解决方案的重要验证 - 无论是从科学还是商业的角度来看</em>。&#34;</p>
<p>Cayman Chemical 和 eXoZymes 正在进行 NCT 的分离过程，同时仍在分析实验数据。预计在完成下游分析和 NCT 提取后，将在后续的新闻稿中发布更多技术细节。由于工作量巨大以及即将到来的假期，这些额外信息预计要到 2026 年初才能公布。</p>
<p><strong>关于 Cayman</strong></p>
<p>Cayman Chemical 通过向全球科学家提供产品和服务，帮助实现研究的可能性。Cayman 的产品包括高质量的生化试剂、生物检测试剂盒、抗体和蛋白质，赋能研究人员理解健康和疾病的生物机制并开发新疗法。Cayman 的科学家在合成、纯化和表征生化物质方面是专家，涵盖从小型药物类杂环到复杂的生物脂质和脂肪酸，并在生物检测和抗体开发、蛋白质表达、结晶和结构确定的各个方面具有高度技能。此外，Cayman 还提供使用 LC-MS/MS、HPLC、GC 等多种技术的广泛分析服务。Cayman 在密歇根州安娜堡和捷克共和国内拉托维采进行仿制药的开发和生产。</p>
<p>了解更多信息，请访问 www.caymanchem.com</p>
<p><strong>关于 eXoZymes</strong></p>
<p>成立于 2019 年，该公司开发了一种生物制造平台 - 作为历史上的首次 - 提供设计、工程、控制和优化自然自身自然过程以生产非常有价值的天然产品的工具和见解，通过一种商业可扩展、可持续和环保的替代方案：外源酶。</p>
<p>外源酶是通过人工智能和生物工程增强的先进酶，能够在不使用活细胞的生物反应器中茁壮成长。外源酶可以用可持续和可扩展的生物解决方案替代有毒的石油化工过程和低效的生化提取，将生物质转化为基本化学品、营养保健品和药物。</p>
<p>通过将酶驱动的化学反应从细胞施加的限制中解放出来，外源酶生物解决方案消除了阻碍合成生物学（SynBio）领域商业成功的规模化瓶颈，使外源酶成为下一代生物制造的代表。</p>
<p>虽然公司 eXoZymes Inc.已将&#34;外源酶&#34;作为一个科学概念引入，但他们并不打算对该概念进行商标注册，因为他们将其视为这一下一代生物制造的广泛采用的新命名法，eXoZymes 旨在引领并成为市场领导者。</p>
<p>了解更多信息，请访问 exozymes.com</p>
<p><strong>eXoZymes 安全港声明</strong></p>
<p>本 <em>新闻稿</em> 包含 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明。前瞻性声明基于某些假设，描述公司的未来计划、战略和预期，通常可以通过使用诸如 “相信”、“期望”、“可能”、“将”、“应该”、“会”、“能够”、“寻求”、“打算”、“计划”、“目标”、“项目”、“估计”、“预期”、“战略”、“未来”、“可能”、“潜在” 或其他类似术语来识别，尽管并非所有前瞻性声明都包含这些识别词。除历史事实声明外，本 <em>新闻稿</em> 中关于公司战略、前景、财务状况、运营、成本、计划和目标的所有声明均为前瞻性声明。实际结果可能因多种原因而显著不同。您应仔细考虑在 eXoZymes 的季度报告（10-Q 表格）、年度报告（10-K 表格）和公司不时向证券交易委员会提交的其他文件中描述的 “风险因素” 部分中的风险和不确定性。这些文件识别并解决可能导致实际事件和结果与前瞻性声明中所包含的内容显著不同的重要风险和不确定性。前瞻性声明仅在作出之日有效。读者应谨慎对待前瞻性声明，不应过度依赖，eXoZymes 不承担任何义务，也不打算更新或修订这些前瞻性声明，无论是由于新信息、未来事件还是其他原因。eXoZymes 不保证其将实现其预期。</p>
<p><strong>eXoZymes 联系方式</strong></p>
<p>Lasse Görlitz，通讯副总裁</p>
<p>(858) 319-7135</p>
<p>press@exozymes.com</p>
<p>https://www.linkedin.com/company/exozymes</p>
<p>https://x.com/exozymes</p>
<p>https://www.youtube.com/@exozymes</p>
<p><strong>来源：</strong> eXoZymes</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNjkxOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNjkxOA"/></p>

EXOZ

<p>eXoZymes Inc. 宣布其基于外源酶的生物制造平台实现了 NCT 生产的 100 倍规模提升，达到超过 99% 的原料转化率。这个里程碑展示了他们的无细胞酶系统的可扩展性和效率，可能会彻底改变生物制造。该过程与 Cayman Chemical 合作执行，突显了其稳健性和可转移性。进一步的技术细节将在 2026 年经过额外分析后发布</p>

<p><strong>Today, eXoZymes Inc. (NASDAQ:EXOZ) (&#34;eXoZymes&#34;)</strong>- a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - announced the successful achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process using its proprietary exozyme-based, cell-free biomanufacturing platform. This effort, with a conversion level of over 99% from feedstock to product, marks a major milestone in the scalability of the exozymes platform.</p>
<div class="lb-trans"><p><strong>今天，eXoZymes Inc.（NASDAQ:EXOZ）（&#34;eXoZymes&#34;）</strong>- 一家利用人工智能增强酶将可持续原料转化为营养保健品和新药物的先锋公司 - 宣布成功实现其 N-trans-caffeoyltyramine（NCT）生产过程的 100 倍规模化，使用其专有的基于外源酶的无细胞生物制造平台。该努力在原料到产品的转化水平超过 99%，标志着外源酶平台可扩展性的一个重要里程碑。</p>
</div><p>&#34; <em>Scaling a complex biocatalytic reaction by 100× while sustaining high feedstock conversion strengthens our belief that exozymes will form the foundation of the next generation of biomanufacturing</em>,&#34; said Michael Heltzen, CEO of eXoZymes. &#34; <em>We're very enthusiastic about this progress and see it as an important inflection point in demonstrating that cell-free, enzyme-driven systems can be engineered to operate reliably at scale. This truly opens the door to producing molecules that have historically been constrained by traditional manufacturing approaches</em>.&#34;</p>
<div class="lb-trans"><p>&#34; <em>在保持高原料转化的同时将复杂的生物催化反应规模化 100 倍，增强了我们对外源酶将成为下一代生物制造基础的信心</em>，&#34; eXoZymes 首席执行官 Michael Heltzen 表示。&#34; <em>我们对这一进展感到非常兴奋，并将其视为一个重要的转折点，证明无细胞、酶驱动的系统可以被设计为在规模上可靠运行。这真正为生产历史上受传统制造方法限制的分子打开了大门</em>。&#34;</p>
</div><p>The scaled reaction maintained exceptionally high conversion efficiency, demonstrating near-complete transformation of input feedstock into target product under large-volume operating conditions. This performance confirms that the exozyme-driven process not only scales linearly but can match - or exceed - conversion levels observed at smaller scales. The batch production was executed using standardized protocols under partner-operated conditions by Cayman Chemical, underscoring the robustness, transferability, and scalability of the process and technology.</p>
<div class="lb-trans"><p>该规模化反应保持了极高的转化效率，在大容量操作条件下几乎完全将输入原料转化为目标产品。这一表现确认了外源酶驱动的过程不仅线性扩展，而且可以匹配或超过在小规模下观察到的转化水平。批量生产是在合作伙伴 Cayman Chemical 的操作条件下，使用标准化协议执行的，突显了该过程和技术的稳健性、可转移性和可扩展性。</p>
</div><p>Dr. Tyler Korman, CSO of eXoZymes, adds, &#34; <em>Scaling while preserving reaction performance has historically been challenging, and this outcome supports the growing body of evidence that cell-free enzyme production pathways - aka exozymes systems - can overcome fundamental limitations associated with traditional biomanufacturing approaches. Achieving over 99% conversion at scale is a significant validation of our exozyme biosolution - both from a scientific as well as a commercial point of view.</em>&#34;</p>
<div class="lb-trans"><p>eXoZymes 首席科学官 Dr. Tyler Korman 补充道，&#34; <em>在保持反应性能的同时进行规模化历来是一个挑战，而这一结果支持了越来越多的证据，表明无细胞酶生产路径 - 即外源酶系统 - 可以克服与传统生物制造方法相关的基本限制。在规模上实现超过 99% 的转化是我们外源酶生物解决方案的重要验证 - 无论是从科学还是商业的角度来看</em>。&#34;</p>
</div><p>Cayman Chemical and eXoZymes are working on the isolation process for NCT as well as still analyzing the data from the experiment. Additional technical details are expected to be published in a subsequent press release following completion of downstream analysis and NCT extraction. Due to the magnitude of the work and the upcoming holidays, this additional information should not be expected until early 2026.</p>
<div class="lb-trans"><p>Cayman Chemical 和 eXoZymes 正在进行 NCT 的分离过程，同时仍在分析实验数据。预计在完成下游分析和 NCT 提取后，将在后续的新闻稿中发布更多技术细节。由于工作量巨大以及即将到来的假期，这些额外信息预计要到 2026 年初才能公布。</p>
</div><p><strong>About Cayman</strong></p>
<div class="lb-trans"><p><strong>关于 Cayman</strong></p>
</div><p>Cayman Chemical helps make research possible by providing products and services to scientists worldwide. Cayman's collection includes high-quality biochemicals, assay kits, antibodies, and proteins, empowering researchers to understand the biological mechanisms of health and disease and develop new therapies. Cayman's scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, and fatty acids, and is highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination. In addition, Cayman offers a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques. Cayman performs generic drug development and production in both Ann Arbor, Michigan and Neratovice, Czech Republic.</p>
<div class="lb-trans"><p>Cayman Chemical 通过向全球科学家提供产品和服务，帮助实现研究的可能性。Cayman 的产品包括高质量的生化试剂、生物检测试剂盒、抗体和蛋白质，赋能研究人员理解健康和疾病的生物机制并开发新疗法。Cayman 的科学家在合成、纯化和表征生化物质方面是专家，涵盖从小型药物类杂环到复杂的生物脂质和脂肪酸，并在生物检测和抗体开发、蛋白质表达、结晶和结构确定的各个方面具有高度技能。此外，Cayman 还提供使用 LC-MS/MS、HPLC、GC 等多种技术的广泛分析服务。Cayman 在密歇根州安娜堡和捷克共和国内拉托维采进行仿制药的开发和生产。</p>
</div><p>Learn more at www.caymanchem.com</p>
<div class="lb-trans"><p>了解更多信息，请访问 www.caymanchem.com</p>
</div><p><strong>About eXoZymes</strong></p>
<div class="lb-trans"><p><strong>关于 eXoZymes</strong></p>
</div><p>Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce very valuable natural products, via a commercially scalable, sustainable, and eco-friendly alternative: exozymes.</p>
<div class="lb-trans"><p>成立于 2019 年，该公司开发了一种生物制造平台 - 作为历史上的首次 - 提供设计、工程、控制和优化自然自身自然过程以生产非常有价值的天然产品的工具和见解，通过一种商业可扩展、可持续和环保的替代方案：外源酶。</p>
</div><p>Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, nutraceuticals and medicines.</p>
<div class="lb-trans"><p>外源酶是通过人工智能和生物工程增强的先进酶，能够在不使用活细胞的生物反应器中茁壮成长。外源酶可以用可持续和可扩展的生物解决方案替代有毒的石油化工过程和低效的生化提取，将生物质转化为基本化学品、营养保健品和药物。</p>
</div><p>By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.</p>
<div class="lb-trans"><p>通过将酶驱动的化学反应从细胞施加的限制中解放出来，外源酶生物解决方案消除了阻碍合成生物学（SynBio）领域商业成功的规模化瓶颈，使外源酶成为下一代生物制造的代表。</p>
</div><p>While the company, eXoZymes Inc., has introduced &#34;exozymes&#34; as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.</p>
<div class="lb-trans"><p>虽然公司 eXoZymes Inc.已将&#34;外源酶&#34;作为一个科学概念引入，但他们并不打算对该概念进行商标注册，因为他们将其视为这一下一代生物制造的广泛采用的新命名法，eXoZymes 旨在引领并成为市场领导者。</p>
</div><p>Learn more at exozymes.com</p>
<div class="lb-trans"><p>了解更多信息，请访问 exozymes.com</p>
</div><p><strong>eXoZymes Safe Harbor</strong></p>
<div class="lb-trans"><p><strong>eXoZymes 安全港声明</strong></p>
</div><p>This <em>press release</em> includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as &#34;believe,&#34; &#34;expect,&#34; &#34;may,&#34; &#34;will,&#34; &#34;should,&#34; &#34;would,&#34; &#34;could,&#34; &#34;seek,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;goal,&#34; &#34;project,&#34; &#34;estimate,&#34; &#34;anticipate,&#34; &#34;strategy,&#34; &#34;future,&#34; &#34;likely,&#34; &#34;potential,&#34; or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this <em>press release</em> regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the &#34;Risk Factors&#34; section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.</p>
<div class="lb-trans"><p>本 <em>新闻稿</em> 包含 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明。前瞻性声明基于某些假设，描述公司的未来计划、战略和预期，通常可以通过使用诸如 “相信”、“期望”、“可能”、“将”、“应该”、“会”、“能够”、“寻求”、“打算”、“计划”、“目标”、“项目”、“估计”、“预期”、“战略”、“未来”、“可能”、“潜在” 或其他类似术语来识别，尽管并非所有前瞻性声明都包含这些识别词。除历史事实声明外，本 <em>新闻稿</em> 中关于公司战略、前景、财务状况、运营、成本、计划和目标的所有声明均为前瞻性声明。实际结果可能因多种原因而显著不同。您应仔细考虑在 eXoZymes 的季度报告（10-Q 表格）、年度报告（10-K 表格）和公司不时向证券交易委员会提交的其他文件中描述的 “风险因素” 部分中的风险和不确定性。这些文件识别并解决可能导致实际事件和结果与前瞻性声明中所包含的内容显著不同的重要风险和不确定性。前瞻性声明仅在作出之日有效。读者应谨慎对待前瞻性声明，不应过度依赖，eXoZymes 不承担任何义务，也不打算更新或修订这些前瞻性声明，无论是由于新信息、未来事件还是其他原因。eXoZymes 不保证其将实现其预期。</p>
</div><p><strong>eXoZymes contact</strong></p>
<div class="lb-trans"><p><strong>eXoZymes 联系方式</strong></p>
</div><p>Lasse Görlitz, VP of Communications</p>
<div class="lb-trans"><p>Lasse Görlitz，通讯副总裁</p>
</div><p>(858) 319-7135</p>
<div class="lb-trans"><p>(858) 319-7135</p>
</div><p>press@exozymes.com</p>
<div class="lb-trans"><p>press@exozymes.com</p>
</div><p>https://www.linkedin.com/company/exozymes</p>
<div class="lb-trans"><p>https://www.linkedin.com/company/exozymes</p>
</div><p>https://x.com/exozymes</p>
<div class="lb-trans"><p>https://x.com/exozymes</p>
</div><p>https://www.youtube.com/@exozymes</p>
<div class="lb-trans"><p>https://www.youtube.com/@exozymes</p>
</div><p><strong>SOURCE:</strong> eXoZymes</p>
<div class="lb-trans"><p><strong>来源：</strong> eXoZymes</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNjkxOA" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1116918"/></p>

eXoZymes 通过使用 Exozymes 实现了 NCT 生产的 100 倍规模放大，展示了近乎完美的原料转化率 | EXOZ 股票新闻